CONMED (NYSE:CNMD) Updates FY 2025 Earnings Guidance

CONMED (NYSE:CNMD) updated its FY 2025 earnings guidance on Wednesday. The company provided earnings per share guidance of 4.250-4.400 for the period, compared to the consensus earnings per share estimate of 4.740. The company issued revenue guidance of $1.3 billion-$1.4 billion, compared to the consensus revenue estimate of $1.4 billion.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on CNMD. Stifel Nicolaus boosted their target price on shares of CONMED from $72.00 to $75.00 and gave the stock a “buy” rating in a research report on Thursday. StockNews.com cut shares of CONMED from a “buy” rating to a “hold” rating in a research report on Friday, November 8th. Wells Fargo & Company reduced their target price on shares of CONMED from $74.00 to $70.00 and set an “equal weight” rating for the company in a research report on Thursday. JPMorgan Chase & Co. cut CONMED from an “overweight” rating to a “neutral” rating and cut their price target for the company from $85.00 to $70.00 in a report on Thursday. Finally, Needham & Company LLC cut their price target on CONMED from $97.00 to $91.00 and set a “buy” rating for the company in a report on Thursday. Three investment analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $77.20.

CONMED Trading Down 0.6 %

Shares of CNMD traded down $0.41 during midday trading on Friday, hitting $66.95. 368,736 shares of the stock were exchanged, compared to its average volume of 444,556. The firm has a market cap of $2.07 billion, a P/E ratio of 15.99, a P/E/G ratio of 1.04 and a beta of 1.46. The stock has a fifty day simple moving average of $70.53 and a 200 day simple moving average of $70.20. CONMED has a 52-week low of $61.05 and a 52-week high of $88.60. The company has a debt-to-equity ratio of 1.01, a quick ratio of 1.06 and a current ratio of 2.27.

CONMED (NYSE:CNMD) last released its earnings results on Wednesday, February 5th. The company reported $1.34 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.20 by $0.14. CONMED had a return on equity of 13.84% and a net margin of 10.23%. On average, research analysts anticipate that CONMED will post 4.03 EPS for the current fiscal year.

CONMED Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Friday, January 3rd. Investors of record on Friday, December 20th were issued a $0.20 dividend. The ex-dividend date was Friday, December 20th. This represents a $0.80 dividend on an annualized basis and a yield of 1.19%. CONMED’s dividend payout ratio (DPR) is presently 18.87%.

CONMED Company Profile

CONMED Corporation, a medical technology company, develops, manufactures, and sells surgical devices and related equipment for surgical procedures worldwide. The company offers orthopedic surgery products, including BioBrace, TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-knot All-Suture Anchors, and Agro Knotless Suture Anchors, which provide clinical solutions to orthopedic surgeons for the augmentation and repair of soft tissue injuries, as well as provides supporting products that enable surgeons to perform minimally invasive sports medicine surgeries.